In a groundbreaking move, the United Arab Emirates (UAE) is set to introduce a nasal spray flu vaccine for the first time, as reported by Emarat Al Youm. This innovative needle-free option will be available in both public and private healthcare centers and hospitals across the country, marking a significant expansion in the nation’s immunization strategy. The vaccine, which covers the same flu strains as the traditional injectable version, is designed for healthy individuals aged 2 to 49 years old. It utilizes a live attenuated virus, making it an ideal choice for children and those who are apprehensive about needles. The Ministry of Health and Prevention emphasized that this new option aims to enhance vaccination coverage rates and provide safe, effective alternatives for the community. Dr. Nada Al Marzouqi, Director of the Public Health and Prevention Department, highlighted that the nasal spray vaccine first received U.S. FDA approval in 2003 for ages 5 to 49, with the age range later extended to include children as young as 2 in 2007. However, the vaccine is not recommended for certain groups, including children under 2, adults over 50, pregnant women, individuals with immune disorders, and those with specific chronic diseases. For these groups, the injectable vaccine or other physician-recommended options remain the preferred choice. The Ministry assured that the nasal spray vaccine is registered in the UAE and subject to rigorous pharmaceutical oversight, with approvals from global regulatory bodies such as the FDA, WHO, and EMA. Additionally, the UAE’s pharmacovigilance program will monitor the vaccine’s side effects and effectiveness to ensure the highest standards of safety and quality.